Vaccination of chemotherapy patients—effect of guideline implementation

Toleman, Michelle S.; Herbert, Katharine; McCarthy, Noel D.; Church, David N.

doi:10.1007/s00520-015-3037-6

Cited by 21 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A guideline implementation study was associated with a significant increase in the rate of pneumococcal vaccination (47 vs. 25%, P= 0.0018) in a tertiary cancer center. 18 A continuous medical education program using live meetings, patient handouts, posters web based applications and organized by an interdisciplinary steering committee significantly improved immunization rates of patients and medical staff.…”

Section: Discussionmentioning

confidence: 99%

Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy.

Akın¹,

Dizdar²,

Özışık³

et al. 2016

UHOD

View full text Add to dashboard Cite

Immunization against vaccine preventable diseases is an essential but mostly overlooked issue in oncology practice. We aimed to investigate the utilization of adult immunization recommendations and the perception of the patients with cancer receiving chemotherapy on immunization. A 15-item questionnaire about immunization in adults with cancer diagnosis was administered to patients with various cancers treated in daycare chemotherapy unit of Hacettepe University Cancer Institute. Total of 229 patients completed the survey. Fifty-four percent of patients were vaccinated at least once, most commonly against influenza and tetanus over 18 years old. Higher rate of participants was opposed to vaccination of patients with cancer diagnosis compared with those who were opposed to vaccination of healthy adults. Vaccination was never recommended in 93% of the participants. Only 9% of patients (n=21) were shot after cancer diagnosis. There was a strong association between doctor's advice and vaccination status. Twelve of 15 patients (80%) who were recommended to be vaccinated did so whereas only 9 of 214 remaining patients (4.2%) were vaccinated. Among those not vaccinated after diagnosis of cancer, most frequent reason was; not recommended by the doctor. Neither vaccination rates nor perceptions on adult immunization differed by age, gender, marital status, presence of co-morbidity or type of cancer. Among adult patients with cancer and receiving chemotherapy, immunization rates were found to be very low. Main reason was the lack of recommendation by the primary physician involved in the treatment, mostly oncologist. Awareness on this issue in physicians, particularly oncologists, may increase vaccination rates. Keywords: Adult immunization, Vaccine preventable disease, Cancer chemotherapy ÖZET Kemoterapi Alan Kanser Hastalarının Aşı DavranışlarıÖnlenebilir hastalıklara karşı aşılanma onkoloji pratiğinde ihmal edilen bir konudur. Bu çalışmada kemoterapi alan kanser hastalarının erişkin aşılanması ile ilgili görüş ve algılarını, düşük aşılanma oranlarının nedenlerini araştırmayı amaçladık. Hacettepe Üniversitesi Onkoloji Hastanesi ayaktan tedavi ünitesinde çeşitli kanser tanıları ile kemoterapi almakta olan erişkin hastalara, erişkin aşılanması ile ilgili 15 sorudan oluşan bir anket uygulandı. Toplam 229 hasta anketi tamamladı. Hastaların %74,7'si erişkinlerin de aşılanması gerektiğini düşünmekteydi. En sık influenza ve tetanos aşısı olmak üzere hastaların %54'ü 18 yaşından sonra en az bir defa aşılanmıştı. Katılımcıların %16,6'sı erişkinlerin aşılamasına karşıydı, daha yüksek oranda bir bölümü ise kanserli hastaların aşılanmasına karşı olduklarını belirtti. Hastaların %93'üne kanser tanısı aldıktan sonra hiç aşı önerilmemişti. Sadece 21 hastanın (%9) tanı sonrası aşı yaptırdığı anlaşılırken en sık influenzaya karşı aşılanma görüldü. Doktor önerisi ve aşılanma durumu arasında anlamlı bir ilişki tespit edildi. Kendisine onkoloğu tarafından aşı önerilen 15 hastanın 12'si(%80) aşılanırken, önerilmeyen 214 hastadan sad...

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy.

Akın¹,

Dizdar²,

Özışık³

et al. 2016

UHOD

View full text Add to dashboard Cite

show abstract

“…In those not vaccinated prior to receiving cytotoxic therapy, some experts recommend delaying vaccination up to 6 months after chemotherapy is completed to ensure greater efficacy. The effectiveness of the current recommendations in reducing disease burden remains unclear, potentially due to underutilization of vaccines in the cancer population resulting from confusion about the utility of vaccination in patients who are receiving myeloablative treatments, even in tertiary cancer centers [93]. …”

Section: Introductionmentioning

confidence: 99%

Bacterial Pneumonia in Patients with Cancer

Wong¹,

Evans

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Synopsis Bacterial pneumonias exact unacceptable morbidity upon patients with cancer. While the risk is often most pronounced amongst patients with treatment-induced cytopenias, the numerous contributors to life-threatening pneumonias in cancer populations range from derangements of lung architecture and swallow function to complex immune defects associated with cytotoxic therapies and graft-vs.-host disease. These structural and immunologic abnormalities often make the diagnosis of pneumonia challenging in cancer patients and impact the composition and duration of therapy. This manuscript addresses the host factors that contribute to pneumonia susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of bacterial pneumonia in cancer patients.

show abstract

“…A recent Cochrane review suggested that there are more benefits than risks for influenza vaccination among cancer patients [19]. Likewise, the use of pneumococcal vaccination to decrease the chances of pneumonia among cancer patients has been recommended by many international bodies [20]. However, adherence to both forms of vaccination was found to be low and more work is needed to improve compliance [21][22][23].…”

Section: Discussionmentioning

confidence: 99%

Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study

Abdel‐Rahman

2020

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Objective: To assess the patterns and trends of influenza and pneumonia-attributed deaths among cancer patients in the United States. Methods: Surveillance, Epidemiology and End Results (SEER) database was accessed and cancer patients diagnosed 1975-2016 who have been included in the SEER-9 registries were included. The primary endpoint of the study is standardized mortality rate (SMR; calculated as observed/ Expected (O/E) ratio for death from influenza and pneumonia among cancer patients). Competing risk analysis was additionally conducted to evaluate the impact of age on influenza/pneumonia-attributed deaths among selected tumor types. Results: The current study evaluates a total of 3,579,199 cancer patients (diagnosed 1975-2016) within the SEER-9 registries; and influenza and pneumonia-attributed deaths represent 1.5% of the recorded deaths for this cohort. SMR for influenza/ pneumoniaattributed death within the first year following cancer diagnosis was 1.88 (1.83-1.94); while SMR for influenza/pneumonia-attributed death following the first year was 1.11 (1.10-1.12). Within the first year following cancer diagnosis, SMR from influenza/pneumonia was higher among individuals with black race (SMR for white race: 1.75 (95% CI: 1.69-1.81) while SMR for black race: 2.90 (95% CI: 2.65-3.16), lung cancer (SMR for lung cancer: 4.39 (95% CI: 4.11-4.69)), head and neck cancer (SMR for oral cavity/ pharynx cancer: 4.02 (95% CI: 3.50-4.59)), lymphomas (SMR for lymphoma: 3.28 (95% CI: 2.92-3.68)), leukemias (SMR for leukemia: 3.32 (95% CI: 2.89-3.80)) and myeloma (SMR for myeloma: 3.91 (95% CI: 3.28-4.63)). Within competing risk analysis, sub-distribution hazard ratio for death from influenza/pneumonia was higher for patients > 70 years versus patients <70 years: for patients with lung cancer: 1.64; 95% CI: 1.49-1.80; for patients with oral cavity/pharynx cancer: 2.13; 95% CI: 1.92-2.36; and for patients with lymphoma: 2.81; 95% CI: 2.57-3.07) Conclusions: Cancer patients are more likely to have influenza/ pneumonia-attributed death compared to the general US population. This risk is higher among patients with lung cancer, head and neck cancer, and hematological malignancies.

show abstract

Vaccination of chemotherapy patients—effect of guideline implementation

Cited by 21 publications

References 14 publications

Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy.

Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy.

Bacterial Pneumonia in Patients with Cancer

Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study

Contact Info

Product

Resources

About